Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bridgewater

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Gut|September 27, 2023
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapyColm J O'Rourke, Massimiliano Salati, Colin Rae, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
The Lancet. Respiratory Medicine|May 14, 2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trialStuart A Taylor, Sue Mallett, Simon Ball, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Gut|September 27, 2023
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapyColm J O'Rourke, Massimiliano Salati, Colin Rae, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
The Lancet. Respiratory Medicine|May 14, 2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trialStuart A Taylor, Sue Mallett, Simon Ball, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
Pageof 13